PCYC-1128-CA – A phase 1b/2 study of Ibrutinib combination therapy
in selected advanced gastrointestinal and genitourinary tumors (bladder,
colon, gastric, renal)
What type of cancer? What stage?
Advanced GU cancer – bladder and renal
Who is eligible?
Advanced GU cancer – bladder and renal
How will I be treated?
Advanced GU cancer – bladder and renal
EA8143
EA8143 – A phase III randomized study comparing Perioperative Nivolumab
cs observation in patients with localized renal cell carcinoma undergoing
nephrectomy.
What type of cancer? What stage?
Renal cell cancer
Who is eligible?
Patients who are to have surgery – disease localized to kidney
How will I be treated?
Nivolumab, an immunotherapy with success in lung and other cancers
CX-839-008
CX-839-008 – A phase III, randomized, placebo controlled study of
Atezolizumab (Anti-PD-L1 antibody) as monotherapy and in combination with
platinum chemotherapy in patients with untreated locally advanced or metastatic
urothelial carcinoma
What type of cancer? What stage?
Renal cell cancer
Who is eligible?
Patients with disease progression after first-line therapy
How will I be treated?
Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated
with Cabozantinib (a small molecule tyrosine kinase inhibitor)
For physicians: more information about this specific trial at
clinicaltrials.gov.
